{"nctId":"NCT00355134","briefTitle":"Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis","startDateStruct":{"date":"2006-06"},"conditions":["Multiple Sclerosis"],"count":1083,"armGroups":[{"label":"Fingolimod 1.25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Fingolimod"]},{"label":"Fingolimod 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Fingolimod"]},{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Fingolimod","otherNames":["FTY720","GilenyaÂ®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis\n* Patients with a relapsing-remitting disease course\n* Patients with expanded disability status scale (EDSS) score of 0-5.5\n\nExclusion Criteria:\n\n* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc.\n* Pregnant or nursing women\n\nFor inclusion in the extension phase patients should complete the 24 month core study with or without 24 months on study drug. If a patient discontinued study drug during the core study due to an adverse event, serious adverse event, laboratory abnormality etc. they would be excluded from the Extension Phase.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24","description":"ARR is the average number of relapses in a year calculated by negative binomial regression as the sum of confirmed relapses of all patients in the group divided by the sum of the number of days on study of all patients in the group and multiplied by 365.25.\n\nA relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\\<37.5C) or known infection. A relapse must be confirmed by the Independent Evaluating Physician (examining neurologist).\n\nARR estimates were calculated from a negative binomial regression model adjusted for treatment, pooled center, number of relapses in the previous 2 years prior to enrollment, and Baseline expanded disability status scale (EDSS).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.203","spread":null},{"groupId":"OG001","value":"0.208","spread":null},{"groupId":"OG002","value":"0.403","spread":null}]}]}]},{"type":"SECONDARY","title":"Aggregate Annualized Relapse Rate (ARR) Estimate up to End of Study","description":"ARR is the average number of relapses in a year calculated by negative binomial regression as the sum of confirmed relapses of all patients in the group divided by the sum of the number of days on study of all patients in the group and multiplied by 365.25.\n\nA relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\\<37.5C) or known infection. A relapse must be confirmed by the Independent Evaluating Physician (examining neurologist).\n\nARR estimates were calculated from a negative binomial regression model adjusted for treatment, pooled center, number of relapses in the previous 2 years prior to enrollment, and Baseline expanded disability status scale (EDSS).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.180","spread":null},{"groupId":"OG001","value":"0.192","spread":null},{"groupId":"OG002","value":"0.363","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Brain Volume","description":"Brain volume was measured using magnetic resonance imaging (MRI). Change from Baseline in brain volume is expressed as a percentage of the Baseline brain volume.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.595","spread":"1.3897"},{"groupId":"OG001","value":"-0.858","spread":"1.2215"},{"groupId":"OG002","value":"-1.279","spread":"1.5028"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.130","spread":"1.6380"},{"groupId":"OG001","value":"-1.266","spread":"1.6941"},{"groupId":"OG002","value":"-1.694","spread":"1.9567"}]}]}]},{"type":"SECONDARY","title":"Number of New or Newly Enlarged T2 Lesions","description":"Inflammatory disease activity was assessed by magnetic resonance imaging (MRI) measurement of the number of new or newly enlarged T2 lesions, by year.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"5.41"},{"groupId":"OG001","value":"2.3","spread":"7.26"},{"groupId":"OG002","value":"8.9","spread":"13.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"2.856"},{"groupId":"OG001","value":"0.45","spread":"1.360"},{"groupId":"OG002","value":"0.63","spread":"1.455"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.448"},{"groupId":"OG001","value":"0.07","spread":"0.258"},{"groupId":"OG002","value":"2.53","spread":"8.741"}]}]}]},{"type":"SECONDARY","title":"Number of Gadolinium-enhanced T1 Lesions","description":"Inflammatory disease activity was assessed by magnetic resonance imaging (MRI) measurement of the number of gadolinium-enhanced T1 lesions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"2.395"},{"groupId":"OG001","value":"0.37","spread":"1.841"},{"groupId":"OG002","value":"1.22","spread":"2.967"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"2.381"},{"groupId":"OG001","value":"0.09","spread":"0.308"},{"groupId":"OG002","value":"0.45","spread":"3.618"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lesion Volume at Month 24 (Core Phase)","description":"Change from Baseline in lesion volume was measured by MRI for T2 lesions and for T1 hypointense lesions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-436.92","spread":"1557.820"},{"groupId":"OG001","value":"-223.27","spread":"1405.459"},{"groupId":"OG002","value":"541.83","spread":"2830.868"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-99.13","spread":"391.210"},{"groupId":"OG001","value":"-111.28","spread":"530.961"},{"groupId":"OG002","value":"-37.68","spread":"671.708"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Free of 3-month Confirmed Disability Progression at Month 24 and End of Study","description":"Disability progression was defined using the following criteria: One point increase from baseline in patients with Baseline Expanded Disability Status Scale (EDSS) score from 0 to 5.0; or half a point increase from Baseline in patients with Baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression was defined as a 3-month sustained increase from Baseline in EDSS score. The EDSS quantifies disability in multiple sclerosis in 8 functional systems; the score ranges from 0 (normal) to 10 (death due to MS). Progression curves were generated by the Kaplan-Meier method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"74.7","spread":null},{"groupId":"OG002","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.64","spread":null},{"groupId":"OG001","value":"58.89","spread":null},{"groupId":"OG002","value":"63.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Free of 6-month Confirmed Disability Progression at Month 24 and End of Study","description":"Disability progression was defined using the following criteria: One point increase from baseline in patients with Baseline Expanded Disability Status Scale (EDSS) score from 0 to 5.0; or half a point increase from Baseline in patients with Baseline EDSS score of 5.5 or above. A 6-month confirmed disability progression was defined as a 6-month sustained increase from Baseline in EDSS score. The EDSS quantifies disability in multiple sclerosis in 8 functional systems; the score ranges from 0 (normal) to 10 (death due to MS). Progression curves were generated by the Kaplan-Meier method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"86.2","spread":null},{"groupId":"OG002","value":"82.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.92","spread":null},{"groupId":"OG001","value":"74.89","spread":null},{"groupId":"OG002","value":"75.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Relapse-free up to Month 24","description":"Estimates of the percentage of participants relapse-free at 24 months were generated from Kaplan-Meier curves of the time to first relapse. A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\\<37.5C) or infection. A relapse was confirmed by an Independent Evaluating Physician.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"71.5","spread":null},{"groupId":"OG002","value":"52.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Relapse-free up to End of Study","description":"Estimates of the percentage of participants relapse-free at end of study were generated from Kaplan-Meier curves of the time to first relapse. A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\\<37.5C) or infection. A relapse was confirmed by an Independent Evaluating Physician.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.88","spread":null},{"groupId":"OG001","value":"66.57","spread":null},{"groupId":"OG002","value":"49.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Z-score","description":"The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.916"},{"groupId":"OG001","value":"0.00","spread":"0.600"},{"groupId":"OG002","value":"-0.07","spread":"0.540"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.011","spread":"0.3499"},{"groupId":"OG001","value":"-0.091","spread":"0.8770"},{"groupId":"OG002","value":"0.019","spread":"0.6304"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":370},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Cough"]}}}